JP2014534196A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534196A5
JP2014534196A5 JP2014535789A JP2014535789A JP2014534196A5 JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5 JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
rasagiline
weight
amount
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059356 external-priority patent/WO2013055687A2/en
Publication of JP2014534196A publication Critical patent/JP2014534196A/ja
Publication of JP2014534196A5 publication Critical patent/JP2014534196A5/ja
Pending legal-status Critical Current

Links

JP2014535789A 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン Pending JP2014534196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
US61/545,422 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (2)

Publication Number Publication Date
JP2014534196A JP2014534196A (ja) 2014-12-18
JP2014534196A5 true JP2014534196A5 (cg-RX-API-DMAC7.html) 2015-12-03

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535789A Pending JP2014534196A (ja) 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン

Country Status (15)

Country Link
US (1) US9346746B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014534196A (cg-RX-API-DMAC7.html)
KR (1) KR20140090996A (cg-RX-API-DMAC7.html)
CN (1) CN103874487A (cg-RX-API-DMAC7.html)
AR (1) AR088297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012323349A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014008555A2 (cg-RX-API-DMAC7.html)
CA (1) CA2851276A1 (cg-RX-API-DMAC7.html)
EA (1) EA201490761A1 (cg-RX-API-DMAC7.html)
HK (1) HK1200315A1 (cg-RX-API-DMAC7.html)
IL (1) IL231721A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014004308A (cg-RX-API-DMAC7.html)
WO (1) WO2013055687A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403043B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217349B9 (en) * 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
KR20100107028A (ko) * 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
EP2285214B1 (en) * 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011042812A1 (en) * 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE346598T1 (de) * 1994-01-10 2006-12-15 Teva Pharma 1-aminoindanderivate und zusammensetzungen hiervon
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DK0966435T3 (da) 1996-12-18 2005-08-15 Teva Pharma Aminoindanderivater
AU775885B2 (en) * 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
US7619077B2 (en) 2003-02-06 2009-11-17 University Of Georgia Research Foundation Nucleic acids encoding a galacturonosyl tranferase enzyme (GALAT1) from arabidopsis
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2007217349B9 (en) 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EA016843B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Таннат разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
KR20100107028A (ko) 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
EP2285214B1 (en) 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011042812A1 (en) 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
BR112013010308A2 (pt) 2010-10-26 2016-07-05 Teva Pharma rasagilina de deutério enriquecido
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Similar Documents

Publication Publication Date Title
JP2014534196A5 (cg-RX-API-DMAC7.html)
JP2014534197A5 (cg-RX-API-DMAC7.html)
JP7266298B2 (ja) プリドピジンの調節放出製剤
AU2011349422B2 (en) Novel pharmaceutical composition
JP2012512907A5 (cg-RX-API-DMAC7.html)
CN104334169B (zh) 包含氨基羧酸盐的固体组合物
CN102114011B (zh) 一种布洛芬缓释制剂及其制备方法
CN101322695B (zh) 双氯芬酸钾缓释胶囊及其生产工艺
CN104758265A (zh) 一种雷诺嗪缓释片药物组合物及其制备方法
CN103610650A (zh) 一种单硝酸异山梨酯缓释微丸及其制剂、制备方法
KR20150092385A (ko) 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
WO2018230504A1 (ja) 顆粒剤、並びに錠剤及びその製造方法
Kim et al. New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs
CN104069068B (zh) 炔丙基半胱氨酸固体分散体及其制备方法和用途
CN104706606B (zh) 一种枸橼酸西地那非片剂及其制备方法
CN107028912B (zh) 一种厄贝沙坦胶囊的制备方法
JP6002869B1 (ja) ジエノゲスト含有錠剤
CN104644601B (zh) 一种卡培他滨片剂
CN106943368A (zh) 米氮平片剂及其制备方法
CN101032484A (zh) 一种噻托溴铵胶囊型吸入粉雾剂
CN104586807B (zh) 用于治疗阿尔茨海默症的缓释制剂及其制备方法
RU2017134794A (ru) Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства
WO2011093612A2 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
CN105663071A (zh) 一种替格瑞洛药物组合物
CN102846574A (zh) 一种硝苯地平控释组合物及其制备方法